Arnon Kater

University Medical Center Amsterdam, Netherlands

Prof . Dr. A.P. Kater’s fundamental, translational and clinical research as a clinical hematologist is focused on lymphatic cancer (lymphoma), particularly chronic lymphatic leukemia (CLL). Together with his colleague at the Academic Medical Center, University of Amsterdam (AMC-UvA) Prof. Eric Eldering, Kater is leading a research group working towards a better understanding of the cellular and molecular processes underlying the emergence and clinical behavior of these illnesses. Together with pharma industries Dr Kater is heavily involved in developments leading to new treatment modalities. Kater was trained as an internist (hematologist) at the AMC-UvA. In 2006 he obtained his doctorate in research into cell death regulation in CLL cells.

From 2008 to 2009 he also worked as a postdoc at the Moores Cancer Center and the Laboratory of Gene Regulation and Signal Transduction at the University of California (San Diego, US). Kater is one of the founders of the Lymphoma and Myeloma Center Amsterdam (LYMMCARE), a specialist knowledge center where the AMC-UvA’s Clinical Hematology, Experimental Immunology and Pathology departments have joined forces since 2012. Within the Amsterdam University Medical Center (a merger of the AMC and the Vumc), he is deputy head of the Dept. of Hematology, vice-dean of the Hematology specialty program and chairman of the clinical research committee.

Kater has been awarded with grants for his research. In 2011, for example, he was awarded a large individual grant by the Dutch Cancer Society to set up his own research group. In 2019 he received an ERC Consolidator grant in order to perform studies on the interactions between CLL cells and the adaptive immune system. He also received grants from the Dutch Cancer foundation, European Union consortia, pharma-industry and various research supporting foundations.

Since September 2014, he has been chair of the Dutch CLL working group at the Hemato-Oncology Foundation for Adults in the Netherlands (HOVON) and since 2020 is member of the HOVON executive board. He is on the editor board of the journals Blood and Haematologica. He is highly active for the Dutch CLL patient advocacy foundation, giving lectures for patients and family, both at meetings and online.